Buscar por Autor Andrade-Villanueva, J.

Ir a: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
O introducir las primeras letras:  
Mostrando resultados 1 a 20 de 28  Siguiente >
Fecha de publicaciónTítuloAutor(es)
2012A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposityMoyle, G.J.; Andrade-Villanueva, J.; Girard, P.-M.; Antinori, A.; Salvato, P.; Bogner, J.R.; Hay, P.; Santos, J.; Astier, L.; Pans, M.; Balogh, A.; Biguenet, S.; Moyle, G.J., St. Stephens Centre, Chelsea and Westminster Hospital, London, United Kingdom; Andrade-Villanueva, J., Hospital Civil de Guadalajara, CUCS, Universidad de Guadalajara, Guadalajara, Mexico; Girard, P.-M., Departments of Virology and Infectious Diseases, Saint-Antoine Hospital, Assitance-Publique Hopitaux de Paris, Paris, France; Antinori, A., Clinical Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy; Salvato, P., Diversified Medical Practices PA, Houston, TX, United States; Bogner, J.R., LMU Medizinische Poliklinik, Munich, Germany; Hay, P., Department of Genitourinary Medicine, St. George's Hospital, London, United Kingdom; Santos, J., Hospital Virgen de la Victoria, M�laga, Spain; Astier, L., Bristol-Myers Squibb Research and Development, Bruxelles, Belgium; Pans, M., Bristol-Myers Squibb Research and Development, Bruxelles, Belgium; Balogh, A., Bristol-Myers Squibb Research and Development, Bruxelles, Belgium; Biguenet, S., Bristol-Myers Squibb Research and Development, Rueil-Malmaison, France
2012A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposityMoyle, G.J.; Andrade-Villanueva, J.; Girard, P.-M.; Antinori, A.; Salvato, P.; Bogner, J.R.; Hay, P.; Santos, J.; Astier, L.; Pans, M.; Balogh, A.; Biguenet, S.; Moyle, G.J., St. Stephens Centre, Chelsea and Westminster Hospital, London, United Kingdom; Andrade-Villanueva, J., Hospital Civil de Guadalajara, CUCS, Universidad de Guadalajara, Guadalajara, Mexico; Girard, P.-M., Departments of Virology and Infectious Diseases, Saint-Antoine Hospital, Assitance-Publique Hopitaux de Paris, Paris, France; Antinori, A., Clinical Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy; Salvato, P., Diversified Medical Practices PA, Houston, TX, United States; Bogner, J.R., LMU Medizinische Poliklinik, Munich, Germany; Hay, P., Department of Genitourinary Medicine, St. George's Hospital, London, United Kingdom; Santos, J., Hospital Virgen de la Victoria, Málaga, Spain; Astier, L., Bristol-Myers Squibb Research and Development, Bruxelles, Belgium; Pans, M., Bristol-Myers Squibb Research and Development, Bruxelles, Belgium; Balogh, A., Bristol-Myers Squibb Research and Development, Bruxelles, Belgium; Biguenet, S., Bristol-Myers Squibb Research and Development, Rueil-Malmaison, France
2013Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: Week 48 resultsGallant, J.E.; Koenig, E.; Andrade-Villanueva, J.; Chetchotisakd, P.; Dejesus, E.; Antunes, F.; Arasteh, K.; Moyle, G.; Rizzardini, G.; Fehr, J.; Liu, Y.; Zhong, L.; Callebaut, C.; Szwarcberg, J.; Rhee, M.S.; Cheng, A.K.; Gallant, J.E., Division of Infectious Diseases, Johns Hopkins University, School of Medicine, Baltimore, MD, United States; Koenig, E., Instituto Dominicano de Estudio-IDEV, Santo-Domingo, Dominican Republic; Andrade-Villanueva, J., HIV Unit, Hospital Civil de Guadalajara, University of Guadalajara, Guadalajara, Mexico; Chetchotisakd, P., Department of Medicine, Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand; Dejesus, E., Orlando Immunology Center, FL, United States; Antunes, F., Infectious Diseases Department, Hospital de Santa Maria, Lisbon, Portugal; Arastéh, K., EPIMED /Vivantes Auguste-Viktoria-Klinikum, Berlin, Germany; Moyle, G., Chelsea and Westminster Hospital, London, United Kingdom; Rizzardini, G., Department of Infectious Diseases, Ospedale Luigi Sacco, Milan, Italy; Fehr, J., Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Switzerland; Liu, Y., Gilead Sciences, Foster City, CA, United States; Zhong, L., Gilead Sciences, Foster City, CA, United States; Callebaut, C., Gilead Sciences, Foster City, CA, United States; Szwarcberg, J., Gilead Sciences, Foster City, CA, United States; Rhee, M.S., Gilead Sciences, Foster City, CA, United States; Cheng, A.K., Gilead Sciences, Foster City, CA, United States
2013Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: Week 48 resultsGallant, J.E.; Koenig, E.; Andrade-Villanueva, J.; Chetchotisakd, P.; Dejesus, E.; Antunes, F.; Arasteh, K.; Moyle, G.; Rizzardini, G.; Fehr, J.; Liu, Y.; Zhong, L.; Callebaut, C.; Szwarcberg, J.; Rhee, M.S.; Cheng, A.K.; Gallant, J.E., Division of Infectious Diseases, Johns Hopkins University, School of Medicine, Baltimore, MD, United States; Koenig, E., Instituto Dominicano de Estudio-IDEV, Santo-Domingo, Dominican Republic; Andrade-Villanueva, J., HIV Unit, Hospital Civil de Guadalajara, University of Guadalajara, Guadalajara, Mexico; Chetchotisakd, P., Department of Medicine, Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand; Dejesus, E., Orlando Immunology Center, FL, United States; Antunes, F., Infectious Diseases Department, Hospital de Santa Maria, Lisbon, Portugal; Arast�h, K., EPIMED /Vivantes Auguste-Viktoria-Klinikum, Berlin, Germany; Moyle, G., Chelsea and Westminster Hospital, London, United Kingdom; Rizzardini, G., Department of Infectious Diseases, Ospedale Luigi Sacco, Milan, Italy; Fehr, J., Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Switzerland; Liu, Y., Gilead Sciences, Foster City, CA, United States; Zhong, L., Gilead Sciences, Foster City, CA, United States; Callebaut, C., Gilead Sciences, Foster City, CA, United States; Szwarcberg, J., Gilead Sciences, Foster City, CA, United States; Rhee, M.S., Gilead Sciences, Foster City, CA, United States; Cheng, A.K., Gilead Sciences, Foster City, CA, United States
1992Comparison of the safety and efficacy of lomefloxacin and trimethoprim/ sulfamethoxazole in the treatment of uncomplicated urinary tract infections: Results from a multicenter studyAndrade-Villanueva, J.; Flores-Gaxiola, A.; Lopez-Guillen, P.; Aguirre-Avalos, G.; Morfin-Otero, R.; Rodriguez-Noriega, E.; Andrade-Villanueva, J., Infectious Diseases Division, Hospital Civil de Guadalajara, Universidad de Guadalajara, Jalisco, Mexico; Flores-Gaxiola, A., Infectious Diseases Division, Hospital Civil de Guadalajara, Universidad de Guadalajara, Jalisco, Mexico; Lopez-Guillen, P., Infectious Diseases Division, Hospital Civil de Guadalajara, Universidad de Guadalajara, Jalisco, Mexico; Aguirre-Avalos, G., Infectious Diseases Division, Hospital Civil de Guadalajara, Universidad de Guadalajara, Jalisco, Mexico; Morfin-Otero, R., Infectious Diseases Division, Hospital Civil de Guadalajara, Universidad de Guadalajara, Jalisco, Mexico; Rodriguez-Noriega, E., Infectious Diseases Division, Hospital Civil de Guadalajara, Universidad de Guadalajara, Jalisco, Mexico, Apartado Postal 2-788, Guadalajara, Jalisco, Mexico
1992Comparison of the safety and efficacy of lomefloxacin and trimethoprim/ sulfamethoxazole in the treatment of uncomplicated urinary tract infections: Results from a multicenter studyAndrade-Villanueva, J.; Flores-Gaxiola, A.; Lopez-Guillen, P.; Aguirre-Avalos, G.; Morfin-Otero, R.; Rodriguez-Noriega, E.; Andrade-Villanueva, J., Infectious Diseases Division, Hospital Civil de Guadalajara, Universidad de Guadalajara, Jalisco, Mexico; Flores-Gaxiola, A., Infectious Diseases Division, Hospital Civil de Guadalajara, Universidad de Guadalajara, Jalisco, Mexico; Lopez-Guillen, P., Infectious Diseases Division, Hospital Civil de Guadalajara, Universidad de Guadalajara, Jalisco, Mexico; Aguirre-Avalos, G., Infectious Diseases Division, Hospital Civil de Guadalajara, Universidad de Guadalajara, Jalisco, Mexico; Morfin-Otero, R., Infectious Diseases Division, Hospital Civil de Guadalajara, Universidad de Guadalajara, Jalisco, Mexico; Rodriguez-Noriega, E., Infectious Diseases Division, Hospital Civil de Guadalajara, Universidad de Guadalajara, Jalisco, Mexico, Apartado Postal 2-788, Guadalajara, Jalisco, Mexico
2013Differences in salivary flow level, xerostomia, and flavor alteration in Mexican HIV patients who did or did not receive antiretroviral therapyLopez-Verdin, S.; Andrade-Villanueva, J.; Zamora-Perez, A.L.; Bologna-Molina, R.; Cervantes-Cabrera, J.J.; Molina-Frechero, N.; López-Verdín, S., Instituto de Investigación en Odontología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44340 Guadalajara, JAL, Mexico; Andrade-Villanueva, J., Unidad de VIH Del Hospital Civil de Guadalajara Fray Antonio Alcalde, 44340 Guadalajara, JAL, Mexico; Zamora-Perez, A.L., Instituto de Investigación en Odontología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44340 Guadalajara, JAL, Mexico; Bologna-Molina, R., Departamento de Investigación, Facultad de Odontología, Universidad Juárez Del Estado de Durango, 34100 Durango, DGO, Mexico, Facultad de Odontología, Universidad de la República (UDELAR), 11600 Montevideo, MVD, Uruguay; Cervantes-Cabrera, J.J., Instituto de Investigación en Odontología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44340 Guadalajara, JAL, Mexico; Molina-Frechero, N., Departamento de Atención A la Salud, Universidad Autónoma Metropolitana, Xochimilco, Calz del Hueso 1100 Villa Quietud, Coyoacán, 04960 Ciudad de México, DF, Mexico
2013Differential response to cold and warm water conditions in Pocillopora colonies from the Central Mexican PacificLopez-Verdin, S.; Andrade-Villanueva, J.; Zamora-Perez, A.L.; Bologna-Molina, R.; Cervantes-Cabrera, J.J.; Molina-Frechero, N.; López-Verdín, S., Instituto de Investigación en Odontología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44340 Guadalajara, JAL, Mexico; Andrade-Villanueva, J., Unidad de VIH Del Hospital Civil de Guadalajara Fray Antonio Alcalde, 44340 Guadalajara, JAL, Mexico; Zamora-Perez, A.L., Instituto de Investigación en Odontología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44340 Guadalajara, JAL, Mexico; Bologna-Molina, R., Departamento de Investigación, Facultad de Odontología, Universidad Juárez Del Estado de Durango, 34100 Durango, DGO, Mexico, Facultad de Odontología, Universidad de la República (UDELAR), 11600 Montevideo, MVD, Uruguay; Cervantes-Cabrera, J.J., Instituto de Investigación en Odontología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 44340 Guadalajara, JAL, Mexico; Molina-Frechero, N., Departamento de Atención A la Salud, Universidad Autónoma Metropolitana, Xochimilco, Calz del Hueso 1100 Villa Quietud, Coyoacán, 04960 Ciudad de México, DF, Mexico
2011Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patientsGathe, J.; Andrade-Villanueva, J.; Santiago, S.; Horban, A.; Nelson, M.; Cahn, P.; Bogner, J.; Spencer, D.; Podzamczer, D.; Yong, C.-L.; Nguyen, T.; Zhang, W.; Drulak, M.; Quinson, A.-M.; Gathe, J., Therapeutic Concepts, Houston, TX, United States; Andrade-Villanueva, J., Hospital Civil de Guadalajara, CUCS, U de G, Guadalajara, Mexico; Santiago, S., Care Resource, Miami, FL, United States; Horban, A., Warsaw Medical University, Hospital for Infectious Diseases, Warsaw, Poland; Nelson, M., Chelsea and Westminster Hospital, London, United Kingdom; Cahn, P., Fundacion Huesped, Buenos Aires, Argentina; Bogner, J., University Hospital of Munich, Downtown Campus, Munich, Germany; Spencer, D., Edenvale, Guateng, South Africa; Podzamczer, D., Hosp. de Bellvitge l'Hospitalet de Llobregat, Barcelona, Spain; Yong, C.-L., Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, United States; Nguyen, T., Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, United States; Zhang, W., Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, United States; Drulak, M., Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, United States; Quinson, A.-M., Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, United States
2011Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patientsGathe, J.; Andrade-Villanueva, J.; Santiago, S.; Horban, A.; Nelson, M.; Cahn, P.; Bogner, J.; Spencer, D.; Podzamczer, D.; Yong, C.-L.; Nguyen, T.; Zhang, W.; Drulak, M.; Quinson, A.-M.; Gathe, J., Therapeutic Concepts, Houston, TX, United States; Andrade-Villanueva, J., Hospital Civil de Guadalajara, CUCS, U de G, Guadalajara, Mexico; Santiago, S., Care Resource, Miami, FL, United States; Horban, A., Warsaw Medical University, Hospital for Infectious Diseases, Warsaw, Poland; Nelson, M., Chelsea and Westminster Hospital, London, United Kingdom; Cahn, P., Fundacion Huesped, Buenos Aires, Argentina; Bogner, J., University Hospital of Munich, Downtown Campus, Munich, Germany; Spencer, D., Edenvale, Guateng, South Africa; Podzamczer, D., Hosp. de Bellvitge l'Hospitalet de Llobregat, Barcelona, Spain; Yong, C.-L., Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, United States; Nguyen, T., Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, United States; Zhang, W., Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, United States; Drulak, M., Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, United States; Quinson, A.-M., Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, United States
2012Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: Randomised, double-blind, phase 3, non-inferiority studyMolina, J.-M.; LaMarca, A.; Andrade-Villanueva, J.; Clotet, B.; Clumeck, N.; Liu, Y.-P.; Zhong, L.; Margot, N.; Cheng, A.K.; Chuck, S.L.; Molina, J.-M., Hôpital Saint Louis, University of Paris Diderot, Paris, France; LaMarca, A., Therafirst Medical Center, Fort Lauderdale, FL, United States; Andrade-Villanueva, J., Hospital Civil de Guadalajara, CUCS, Universidad de Guadalajara, Guadalajara, Mexico; Clotet, B., Fundacio Irsicaixa, Hospital Universitari Germans Trias i Pujol, UAB, Badalona, Spain; Clumeck, N., CHU St Pierre, Brussels, Belgium; Liu, Y.-P., Gilead Sciences, Foster City, CA, United States; Zhong, L., Gilead Sciences, Foster City, CA, United States; Margot, N., Gilead Sciences, Foster City, CA, United States; Cheng, A.K., Gilead Sciences, Foster City, CA, United States; Chuck, S.L., Gilead Sciences, Foster City, CA, United States
2012Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: Randomised, double-blind, phase 3, non-inferiority studyMolina, J.-M.; LaMarca, A.; Andrade-Villanueva, J.; Clotet, B.; Clumeck, N.; Liu, Y.-P.; Zhong, L.; Margot, N.; Cheng, A.K.; Chuck, S.L.; Molina, J.-M., H�pital Saint Louis, University of Paris Diderot, Paris, France; LaMarca, A., Therafirst Medical Center, Fort Lauderdale, FL, United States; Andrade-Villanueva, J., Hospital Civil de Guadalajara, CUCS, Universidad de Guadalajara, Guadalajara, Mexico; Clotet, B., Fundacio Irsicaixa, Hospital Universitari Germans Trias i Pujol, UAB, Badalona, Spain; Clumeck, N., CHU St Pierre, Brussels, Belgium; Liu, Y.-P., Gilead Sciences, Foster City, CA, United States; Zhong, L., Gilead Sciences, Foster City, CA, United States; Margot, N., Gilead Sciences, Foster City, CA, United States; Cheng, A.K., Gilead Sciences, Foster City, CA, United States; Chuck, S.L., Gilead Sciences, Foster City, CA, United States
2011National prevalence and trends of hiv transmitted drug resistance in mexicoAvila-Rios, S.; Garcia-Morales, C.; Garrido-Rodriguez, D.; Ormsby, C.E.; Hernandez-Juan, R.; Andrade-Villanueva, J.; Gonzalez-Hernandez, L.A.; Torres-Escobar, I.; Navarro-Alvarez, S.; Reyes-Teran, G.; Avila-Ríos, S., Centro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico; García-Morales, C., Centro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico; Garrido-Rodríguez, D., Centro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico; Ormsby, C.E., Centro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico; Hernández-Juan, R., Centro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico; Andrade-Villanueva, J., Unidad de VIH/SIDA, Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico; González-Hernández, L.A., Unidad de VIH/SIDA, Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico; Torres-Escobar, I., Hospital General de Puebla, Puebla, Puebla, Mexico, Facultad de Medicina, Benemérita Universidad Autónoma de Puebla, Puebla, Puebla, Mexico; Navarro-Álvarez, S., Hospital General de Tijuana, Tijuana, Baja California, Mexico; Reyes-Terán, G., Centro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico
2011National prevalence and trends of hiv transmitted drug resistance in mexicoAvila-Rios, S.; Garcia-Morales, C.; Garrido-Rodriguez, D.; Ormsby, C.E.; Hernandez-Juan, R.; Andrade-Villanueva, J.; Gonzalez-Hernandez, L.A.; Torres-Escobar, I.; Navarro-Alvarez, S.; Reyes-Teran, G.; Avila-R�os, S., Centro de Investigaci�n en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico; Garc�a-Morales, C., Centro de Investigaci�n en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico; Garrido-Rodr�guez, D., Centro de Investigaci�n en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico; Ormsby, C.E., Centro de Investigaci�n en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico; Hern�ndez-Juan, R., Centro de Investigaci�n en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico; Andrade-Villanueva, J., Unidad de VIH/SIDA, Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico; Gonz�lez-Hern�ndez, L.A., Unidad de VIH/SIDA, Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico; Torres-Escobar, I., Hospital General de Puebla, Puebla, Puebla, Mexico, Facultad de Medicina, Benem�rita Universidad Aut�noma de Puebla, Puebla, Puebla, Mexico; Navarro-�lvarez, S., Hospital General de Tijuana, Tijuana, Baja California, Mexico; Reyes-Ter�n, G., Centro de Investigaci�n en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico
2011Pilot, randomized study assessing safety, tolerability and efficacy of simplified LPV/r maintenance therapy in HIV patients on the 1 st PI-based regimenCahn, P.; Montaner, J.; Junod, P.; Patterson, P.; Krolewiecki, A.; Andrade-Villanueva, J.; Cassetti, I.; Sierra-Madero, J.; Casiro, A.D.; Bortolozzi, R.; Lupo, S.H.; Longo, N.; Rampakakis, E.; Ackad, N.; Sampalis, J.S.; Cahn, P., Fundacion Huesped, Buenos Aires, Argentina; Montaner, J., University of British Columbia, Vancouver, Canada; Junod, P., Clinique Médicale du Quartier Latin, Montréal, Canada; Patterson, P., Fundacion Huesped, Buenos Aires, Argentina; Krolewiecki, A., Fundacion Huesped, Buenos Aires, Argentina; Andrade-Villanueva, J., Antiguo Hospital Civil de Guadalajara Fray Antonio Alcalde, CUCS, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico; Cassetti, I., Helios Salud, Buenos Aires, Argentina; Sierra-Madero, J., Instituto Nacional de Ciencias Medicas y Nutricion, Mexico, Mexico; Casiró, A.D., Hospital General de Agudos Teodoro Alvarez, Buenos Aires, Argentina; Bortolozzi, R., División Estudios Clínicos, Centro Diagnóstico Médico de Alta Complejidad S.A. (CIBIC), Santa Fé, Argentina; Lupo, S.H., Instituto CAICI, Santa Fé, Argentina; Longo, N., JSS Medical Research, Westmount, Canada; Rampakakis, E., JSS Medical Research, Westmount, Canada; Ackad, N., Abbott Laboratories, Montréal, Canada; Sampalis, J.S., JSS Medical Research, Westmount, Canada, McGill University, Montréal, Canada
2011Pollination between maize and teosinte: An important determinant of gene flow in MexicoCahn, P.; Montaner, J.; Junod, P.; Patterson, P.; Krolewiecki, A.; Andrade-Villanueva, J.; Cassetti, I.; Sierra-Madero, J.; Casiro, A.D.; Bortolozzi, R.; Lupo, S.H.; Longo, N.; Rampakakis, E.; Ackad, N.; Sampalis, J.S.; Cahn, P., Fundacion Huesped, Buenos Aires, Argentina; Montaner, J., University of British Columbia, Vancouver, Canada; Junod, P., Clinique Médicale du Quartier Latin, Montreal, Canada; Patterson, P., Fundacion Huesped, Buenos Aires, Argentina; Krolewiecki, A., Fundacion Huesped, Buenos Aires, Argentina; Andrade-Villanueva, J., Antiguo Hospital Civil de Guadalajara Fray Antonio Alcalde, CUCS, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico; Cassetti, I., Helios Salud, Buenos Aires, Argentina; Sierra-Madero, J., Instituto Nacional de Ciencias Medicas y Nutricion, Mexico, Mexico; Casir , A.D., Hospital General de Agudos Teodoro Alvarez, Buenos Aires, Argentina; Bortolozzi, R., División Estudios Clúnicos, Centro Diagnóstico Médico de Alta Complejidad S.A. (CIBIC), Santa Fé, Argentina; Lupo, S.H., Instituto CAICI, Santa Fé, Argentina; Longo, N., JSS Medical Research, Westmount, Canada; Rampakakis, E., JSS Medical Research, Westmount, Canada; Ackad, N., Abbott Laboratories, Montreal, Canada; Sampalis, J.S., JSS Medical Research, Westmount, Canada, McGill University, Montreal, Canada
1989Quinolones in the treatment of Salmonella carriers.Rodriguez-Noriega, E.; Andrade-Villanueva, J.; Amaya-Tapia, G.; Rodríguez-Noriega, E., Infectious Diseases Division, Universidad de Guadalajara, Complejo Médico, Hospital Civil de Guadalajara, Jalisco, Mexico.; Andrade-Villanueva, J., Infectious Diseases Division, Universidad de Guadalajara, Complejo Médico, Hospital Civil de Guadalajara, Jalisco, Mexico.; Amaya-Tapia, G., Infectious Diseases Division, Universidad de Guadalajara, Complejo Médico, Hospital Civil de Guadalajara, Jalisco, Mexico.
1989Quinolones in the treatment of Salmonella carriers.Rodriguez-Noriega, E.; Andrade-Villanueva, J.; Amaya-Tapia, G.; Rodr�guez-Noriega, E., Infectious Diseases Division, Universidad de Guadalajara, Complejo M�dico, Hospital Civil de Guadalajara, Jalisco, Mexico.; Andrade-Villanueva, J., Infectious Diseases Division, Universidad de Guadalajara, Complejo M�dico, Hospital Civil de Guadalajara, Jalisco, Mexico.; Amaya-Tapia, G., Infectious Diseases Division, Universidad de Guadalajara, Complejo M�dico, Hospital Civil de Guadalajara, Jalisco, Mexico.
2011Raltegravir once daily or twice daily in previously untreated patients with HIV-1: A randomised, active-controlled, phase 3 non-inferiority trialEron, J.J.; Rockstroh, J.K.; Reynes, J.; Andrade-Villanueva, J.; Ramalho-Madruga, J.V.; Bekker, L.-G.; Young, B.; Katlama, C.; Gatell-Artigas, J.M.; Arribas, J.R.; Nelson, M.; Campbell, H.; Zhao, J.; Rodgers, A.J.; Rizk, M.L.; Wenning, L.; Miller, M.D.; Hazuda, D.; DiNubile, M.J.; Leavitt, R.; Isaacs, R.; Robertson, M.N.; Sklar, P.; Nguyen, B.-Y.; Eron, J.J., University of North Carolina School of Medicine, Chapel Hill, NC, United States; Rockstroh, J.K., Oberarzt an der Medizinischen Universitätsklinik, Bonn, Germany; Reynes, J., Centre Hospitalier Universitaire Gui de Chauliac, Montpellier, France; Andrade-Villanueva, J., Hospital Civil de Guadalajara, Universidad de Guadalajara, Guadalajara, Mexico; Ramalho-Madruga, J.V., Centro de Referencia e Treinamento DST/AIDS, Sao Paulo, Brazil; Bekker, L.-G., University of Cape Town, Cape Town, South Africa; Young, B., Rocky Mountain CARES/Denver Infectious Disease Consultants, Denver, CO, United States; Katlama, C., Hôpital Pitié-Salpêtrière, Paris, France; Gatell-Artigas, J.M., Hospital Clinic I Provincial de Barcelona, Barcelona, Spain; Arribas, J.R., Hospital Universitario La Paz, Instituto de Investigación Hospital, Universitario La Paz, Madrid, Spain; Nelson, M., St Stephen's AIDS Trust, Crusaid Research Institute, London, United Kingdom; Campbell, H., Merck Research Laboratories, North Wales, PA, United States; Zhao, J., Oberarzt an der Medizinischen Universitätsklinik, Bonn, Germany; Rodgers, A.J., Oberarzt an der Medizinischen Universitätsklinik, Bonn, Germany; Rizk, M.L., Oberarzt an der Medizinischen Universitätsklinik, Bonn, Germany; Wenning, L., Oberarzt an der Medizinischen Universitätsklinik, Bonn, Germany; Miller, M.D., Oberarzt an der Medizinischen Universitätsklinik, Bonn, Germany; Hazuda, D., Oberarzt an der Medizinischen Universitätsklinik, Bonn, Germany; DiNubile, M.J., Oberarzt an der Medizinischen Universitätsklinik, Bonn, Germany; Leavitt, R., Oberarzt an der Medizinischen Universitätsklinik, Bonn, Germany; Isaacs, R., Oberarzt an der Medizinischen Universitätsklinik, Bonn, Germany; Robertson, M.N., Oberarzt an der Medizinischen Universitätsklinik, Bonn, Germany; Sklar, P., Oberarzt an der Medizinischen Universitätsklinik, Bonn, Germany; Nguyen, B.-Y., Oberarzt an der Medizinischen Universitätsklinik, Bonn, Germany
2011Random period arc-induced long-period fiber gratingsEron, J.J.; Rockstroh, J.K.; Reynes, J.; Andrade-Villanueva, J.; Ramalho-Madruga, J.V.; Bekker, L.-G.; Young, B.; Katlama, C.; Gatell-Artigas, J.M.; Arribas, J.R.; Nelson, M.; Campbell, H.; Zhao, J.; Rodgers, A.J.; Rizk, M.L.; Wenning, L.; Miller, M.D.; Hazuda, D.; DiNubile, M.J.; Leavitt, R.; Isaacs, R.; Robertson, M.N.; Sklar, P.; Nguyen, B.-Y.; Eron, J.J., University of North Carolina School of Medicine, Chapel Hill, NC, United States; Rockstroh, J.K., Oberarzt an der Medizinischen Universitytsklinik, Bonn, Germany; Reynes, J., Centre Hospitalier Universitaire Gui de Chauliac, Montpellier, France; Andrade-Villanueva, J., Hospital Civil de Guadalajara, Universidad de Guadalajara, Guadalajara, Mexico; Ramalho-Madruga, J.V., Centro de Referencia e Treinamento DST/AIDS, Sao Paulo, Brazil; Bekker, L.-G., University of Cape Town, Cape Town, South Africa; Young, B., Rocky Mountain CARES/Denver Infectious Disease Consultants, Denver, CO, United States; Katlama, C., Hospital Pitié-Salpetriere, Paris, France; Gatell-Artigas, J.M., Hospital Clinic I Provincial de Barcelona, Barcelona, Spain; Arribas, J.R., Hospital Universitario La Paz, Instituto de Investigación Hospital, Universitario La Paz, Madrid, Spain; Nelson, M., St Stephen's AIDS Trust, Crusaid Research Institute, London, United Kingdom; Campbell, H., Merck Research Laboratories, North Wales, PA, United States; Zhao, J., Oberarzt an der Medizinischen Universitytsklinik, Bonn, Germany; Rodgers, A.J., Oberarzt an der Medizinischen Universitytsklinik, Bonn, Germany; Rizk, M.L., Oberarzt an der Medizinischen Universitytsklinik, Bonn, Germany; Wenning, L., Oberarzt an der Medizinischen Universitytsklinik, Bonn, Germany; Miller, M.D., Oberarzt an der Medizinischen Universitytsklinik, Bonn, Germany; Hazuda, D., Oberarzt an der Medizinischen Universitytsklinik, Bonn, Germany; DiNubile, M.J., Oberarzt an der Medizinischen Universitytsklinik, Bonn, Germany; Leavitt, R., Oberarzt an der Medizinischen Universitytsklinik, Bonn, Germany; Isaacs, R., Oberarzt an der Medizinischen Universitytsklinik, Bonn, Germany; Robertson, M.N., Oberarzt an der Medizinischen Universitytsklinik, Bonn, Germany; Sklar, P., Oberarzt an der Medizinischen Universitytsklinik, Bonn, Germany; Nguyen, B.-Y., Oberarzt an der Medizinischen Universitytsklinik, Bonn, Germany